A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs IM 156 (Primary)
- Indications Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Lymphoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ImmunoMet Therapeutics
- 24 Jul 2019 Planned End Date changed from 1 Oct 2019 to 1 Jan 2020.
- 24 Jul 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Nov 2019.
- 23 Apr 2019 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History